Letter to the editor: Toward more precise and translational assessment of RAMIE in esophageal cancer surgery

HIGHLIGHTS RAMIE is not a uniform technique; its substantial platform and technical heterogeneity challenge the validity of pooled comparative estimates. Long-term survival comparisons are limited by unbalanced follow-up and lack of adjustment for essential pathological prognostic factors. Distinct biological effects of different neoadjuvant regimens influence surgical difficulty and outcomes, making binary classification inadequate. A system-level, biologically informed analytical framework is needed to more accurately evaluate the real-world clinical value of RAMIE. To the Editor, We read the meta-analysis by Yang et al with great interest, as it provides a timely synthesis of perioperative and oncologic outcomes across RAMIE, MIE, and OE[1]. With the rapid global expansion of RAMIE and its growing role within immunotherapy-based multimodal care, high-quality comparative evidence is increasingly important. Several methodological considerations, however, warrant further attention to refine the clinical and translational interpretation of the findings. This study complies with the TITAN 2025 guidelines for transparent and ethical reporting of AI-assisted research[2]. A key limitation is the assumption that RAMIE represents a single, uniform intervention. In real-world practice, RAMIE comprises diverse platform generations, lymphadenectomy strategies, conduit designs, and perfusion assessment practices, all shaped by center workflow and surgeon proficiency[3]. This variability exceeds that typically observed in conventional MIE or open surgery and challenges the interpretability of a single pooled effect. Aggregating these configurations may obscure benefits achieved in mature high-volume programs, conceal failure modes during early adoption and prevent identification of the specific technical components associated with improved outcomes. Comparative studies that stratify results by platform, experience level, anastomotic technique and adjunct imaging would more effectively guide training, credentialing and investment decisions. In addition, the meta-analysis did not account for the substantial heterogeneity in robotic platform evolution itself. The transition from early-generation systems with limited articulation to newer platforms offering enhanced 3D visualization, advanced energy devices and improved ergonomics has meaningfully altered dissection stability, recurrent laryngeal nerve exposure and microvascular control. Pooling outcomes across these technological eras risks conflating learning-curve–related morbidity with true device-associated performance, thereby obscuring the incremental benefits observed in contemporary robotic practice. Incorporating platform-generation subgroup analyses would strengthen the causal inference regarding RAMIE-specific advantages. The conclusion of comparable long-term survival also requires caution. The synthesis did not adjust for key pathological determinants of prognosis, including ypT and ypN stage, margin involvement, lymph vascular and perineural invasion and tumor regression grade[4]. Follow-up duration was similarly unbalanced, with RAMIE cohorts drawn from more recent periods and therefore capturing fewer late recurrences. Under these circumstances, pooled hazard ratios may reflect differences in follow-up maturity rather than biological equivalence. This issue is amplified in the era of neoadjuvant immunotherapy, where nodal sterilization and altered recurrence dynamics influence both operative complexity and survival interpretation[5]. Future analyses should incorporate stage-adjusted and regimen-adjusted survival curves, fixed time point comparisons and harmonized recurrence definitions. Another limitation of significant clinical relevance is the reduction of neoadjuvant therapy to a binary variable. Regimens such as CROSS chemoradiation, triplet chemotherapy, and immunotherapy-based chemoradiation produce distinct inflammatory and fibrotic environments that directly influence lymphadenectomy difficulty, recurrent laryngeal nerve vulnerability and anastomotic durability[6]. These tissue phenotypes are meaningful effect modifiers and should be treated as explicit analytical strata rather than combined into a single category. Moreover, the interaction between regimen response and robotic performance warrants more rigorous exploration. Patients demonstrating major pathologic response after immunotherapy often exhibit dense fibrosis around the aortopulmonary window and airway structures, creating anatomical constraints that may selectively test the precision advantages of RAMIE. Conversely, poor responders may present with persistent bulky nodes requiring en bloc dissection that challenges both robotic and thoracoscopic approaches. Without integrating biological response profiles, comparisons between modalities risk overlooking essential treatment–technology interactions. Looking forward, the field would benefit from analytical frameworks that view esophagectomy as the culmination of a broader biological and system-level process. Integrating data on regimen response, robotic platform capability, surgeon learning trajectories and perioperative pathways could generate models that more accurately reflect real-world determinants of risk and recovery. Multi-institutional registries with standardized datasets and continuous quality metrics would support this evolution and inform responsible, equitable dissemination of RAMIE. We offer these considerations with the aim of strengthening the methodological foundations needed to guide the safe, evidence-based and patient-centered integration of RAMIE into modern esophageal cancer care.